180 related articles for article (PubMed ID: 12811284)
1. Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases.
Poynton AR; Nelson MC; McCance SE; Levine RL; O'Leary PF
Spine (Phila Pa 1976); 2003 Jun; 28(12):E221-3. PubMed ID: 12811284
[TBL] [Abstract][Full Text] [Related]
2. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency.
Cmolik BL; Spero JA; Magovern GJ; Clark RE
J Thorac Cardiovasc Surg; 1993 Feb; 105(2):222-7; discussion 227-8. PubMed ID: 8429648
[TBL] [Abstract][Full Text] [Related]
3. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure.
Savage WJ; Kickler TS; Takemoto CM
Pediatr Blood Cancer; 2007 Dec; 49(7):1025-9. PubMed ID: 16526049
[TBL] [Abstract][Full Text] [Related]
4. Development of antibodies to human thrombin and factor V in a pediatric patient exposed to topical bovine thrombin.
Lo CY; Jones C; Glader B; Zehnder JL
Pediatr Blood Cancer; 2010 Dec; 55(6):1195-7. PubMed ID: 20979176
[TBL] [Abstract][Full Text] [Related]
5. Development of factor V and thrombin inhibitors in children following bovine thrombin exposure during cardiac surgery: a report of three cases.
Bomgaars L; Carberry K; Fraser C; West A; Teruya J
Congenit Heart Dis; 2010; 5(3):303-8. PubMed ID: 20576051
[TBL] [Abstract][Full Text] [Related]
6. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors.
Berruyer M; Amiral J; Ffrench P; Belleville J; Bastien O; Clerc J; Kassir A; Estanove S; Dechavanne M
J Thorac Cardiovasc Surg; 1993 May; 105(5):892-7. PubMed ID: 8487567
[TBL] [Abstract][Full Text] [Related]
7. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases.
Spero JA
J Neurosurg; 1993 May; 78(5):817-20. PubMed ID: 8468613
[TBL] [Abstract][Full Text] [Related]
8. Acquired factor V deficiency associated with exposure to bovine thrombin in a burn patient.
Foster KN; Kim H; Potter K; Matthews MR; Pressman M; Caruso DM
J Burn Care Res; 2010; 31(2):353-60. PubMed ID: 20182366
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.
Chouhan VD; De La Cadena RA; Nagaswami C; Weisel JW; Kajani M; Rao AK
Thromb Haemost; 1997 Feb; 77(2):343-9. PubMed ID: 9157594
[TBL] [Abstract][Full Text] [Related]
10. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report.
Adams JD; Jones S; Brost BC
J Reprod Med; 2001 Oct; 46(10):909-12. PubMed ID: 11725736
[TBL] [Abstract][Full Text] [Related]
11. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin.
Crow SS; Sullivan VV; Aysola AE; Key NS; Harker-Murray P; Foker JE; Steiner ME
Ann Thorac Surg; 2007 Apr; 83(4):1547-9. PubMed ID: 17383385
[TBL] [Abstract][Full Text] [Related]
12. Immune-mediated coagulopathy: a case report.
Naoum JJ
Pharmacotherapy; 2009 Jul; 29(7 Pt 2):13S-7S. PubMed ID: 19558280
[TBL] [Abstract][Full Text] [Related]
13. Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
Caers J; Reekmans A; Jochmans K; Naegels S; Mana F; Urbain D; Reynaert H
Endoscopy; 2003 Jun; 35(6):542-4. PubMed ID: 12783357
[TBL] [Abstract][Full Text] [Related]
14. Relative purity of thrombin-based hemostatic agents used in surgery.
Schoenecker JG; Johnson RK; Fields RC; Lesher AP; Domzalski T; Baig K; Lawson JH; Parker W
J Am Coll Surg; 2003 Oct; 197(4):580-90. PubMed ID: 14522327
[TBL] [Abstract][Full Text] [Related]
15. Antihuman factor V antibodies after use of relatively pure bovine thrombin.
Lawson JH; Lynn KA; Vanmatre RM; Domzalski T; Klemp KF; Ortel TL; Niklason LE; Parker W
Ann Thorac Surg; 2005 Mar; 79(3):1037-8. PubMed ID: 15734434
[TBL] [Abstract][Full Text] [Related]
16. High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors.
de Raucourt E; Barbier C; Sinda P; Dib M; Peltier JY; Ternisien C
Am J Hematol; 2003 Nov; 74(3):187-90. PubMed ID: 14587047
[TBL] [Abstract][Full Text] [Related]
17. Acquired factor V inhibitor after exposure to topical human thrombin related to an otorhinolaryngological procedure.
Donohoe K; Levine R
J Thromb Haemost; 2015 Oct; 13(10):1787-9. PubMed ID: 26270511
[TBL] [Abstract][Full Text] [Related]
18. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin.
Tarantino MD; Ross MP; Daniels TM; Nichols WL
J Pediatr Hematol Oncol; 1997; 19(3):226-31. PubMed ID: 9201145
[TBL] [Abstract][Full Text] [Related]
19. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure.
Streiff MB; Ness PM
Transfusion; 2002 Jan; 42(1):18-26. PubMed ID: 11896308
[TBL] [Abstract][Full Text] [Related]
20. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery.
Doria C; Fischer CP; Wood CG; Li PM; Marra S; Hart J
Curr Med Res Opin; 2008 Mar; 24(3):785-94. PubMed ID: 18241525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
